PDS completes End-of-Phase 2 meeting with FDA

NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of unresectable, recurrent/metastatic human papilloma virus (HPV) 16-positive head and neck squamous cell carcinoma (HNSCC).

Earlier this year, the FDA granted Fast Track designation to the combination of PDS0101 and KEYTRUDA® (pembrolizumab) for the treatment of HPV16-positive HNSCC. The FDA’s Fast Track designation program is designed to aid in the development and to expedite the review of drug candidate applications that could potentially treat serious or life-threatening conditions. Treatments granted this designation are given the opportunity to have more frequent meetings and interactions with the FDA throughout the entire drug development and review process, with the goal of moving promising new drugs more rapidly through the process.

Dr. Frank Bedu-Addo, Chief Executive Officer of PDS Biotech commented: “We are very pleased with the guidance received from FDA on key elements of the clinical program that will support the submission of a Biologics License Application (BLA) for our lead asset PDS0101. The interim safety and efficacy data we presented to the FDA has allowed us to move into a registrational trial ahead of our projected schedule. This, along with the recent capital raise, allows us to efficiently advance our clinical programs.

“PDS0101 represents a potentially transformative treatment approach for HPV16-positive HNSCC patients. We are committed to providing physicians and patients a possibly more effective and safer treatment option to address this debilitating and deadly disease.”

Dr. Ilian Iliev, CEO of NetScientific, commented: “We are pleased with PDS’ continued and systematic progress on its business objectives, despite unfavourable capital markets conditions. Building on momentum from the FDA Fast Track designation in June 2022, and the subsequent $35m venture debt facility in August 2022, PDS is now well positioned for further progress in its PDS101 clinical programme.”

The full text of the announcement from PDS Biotechnology is available online here: PDS Biotech – PDS Biotech – PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS0101 in Combination With KEYTRUDA®


Related News